Related Experiment Video
Updated: Jan 30, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions
Qianting Zhang1, Mu Xiao1, Shuchen Gu1
1MOE Key Laboratory of Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, China.
Abstract:
Loss of TGF-β tumour suppressive response is a hallmark of human cancers. As a central player in TGF-β signal transduction, SMAD4 (also known as DPC4) is frequently mutated or deleted in gastrointestinal and pancreatic cancer. However, such genetic alterations are rare in most cancer types and the underlying mechanism for TGF-β resistance is not understood. Here we describe a mechanism of TGF-β resistance in ALK-positive tumours, including lymphoma, lung cancer and neuroblastoma. We demonstrate that, in ALK-positive tumours, ALK directly phosphorylates SMAD4 at Tyr 95. Phosphorylated SMAD4 is unable to bind to DNA and fails to elicit TGF-β gene responses and tumour suppressing responses. Chemical or genetic interference of the oncogenic ALK restores TGF-β responses in ALK-positive tumour cells. These findings reveal that SMAD4 is tyrosine-phosphorylated by an oncogenic tyrosine kinase during tumorigenesis. This suggests a mechanism by which SMAD4 is inactivated in cancers and provides guidance for targeted therapies in ALK-positive cancers.
Insights
Transforming growth factor beta (TGF-β) resistance in ALK-positive cancers occurs when ALK phosphorylates SMAD4, blocking its tumor-suppressing function. Restoring TGF-β signaling via ALK inhibition offers a targeted therapy approach.
Area of Science:
- Oncology
- Molecular Biology
- Signal Transduction
Background:
- Loss of TGF-β tumor-suppressive response is a hallmark of human cancers.
- SMAD4, a key player in TGF-β signaling, is often altered in gastrointestinal and pancreatic cancers, but mechanisms of resistance in other cancer types remain unclear.
- ALK-positive tumors, including lymphoma, lung cancer, and neuroblastoma, exhibit resistance to TGF-β signaling.
Purpose of the Study:
- To elucidate the mechanism of TGF-β resistance in ALK-positive tumors.
- To investigate the role of ALK in SMAD4 regulation and TGF-β signaling.
- To identify potential therapeutic strategies targeting ALK-positive cancers.
Main Methods:
- Investigated ALK-positive tumor cell lines (lymphoma, lung cancer, neuroblastoma).
- Utilized biochemical assays to examine ALK-mediated phosphorylation of SMAD4.
- Assessed the impact of SMAD4 phosphorylation on DNA binding and gene expression.
- Evaluated the efficacy of chemical and genetic ALK inhibition in restoring TGF-β responses.
Main Results:
- ALK directly phosphorylates SMAD4 at Tyrosine 95 (Tyr95) in ALK-positive tumors.
- Phosphorylated SMAD4 is impaired in DNA binding, leading to the loss of TGF-β-mediated gene responses and tumor suppression.
- Interference with oncogenic ALK (chemically or genetically) restores SMAD4 function and TGF-β responses in these cancer cells.
Conclusions:
- SMAD4 inactivation occurs through tyrosine phosphorylation by the oncogenic ALK kinase in ALK-positive cancers.
- This mechanism explains TGF-β resistance in these tumor types.
- Targeting ALK offers a promising therapeutic strategy for ALK-positive cancers exhibiting SMAD4-mediated TGF-β resistance.
Related Concept Videos
TGF - β Signaling Pathway
Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Intellectual Disability
Learning Disabilities
Dyslexia
Dyslexia is a...
Receptor Tyrosine Kinases

